Polygenic risk scores and early manifestations of attention-deficit/hyperactivity disorder.

Competing Interests: Henrik Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention‐deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. Henrik Larsson is Editor‐in‐Chief of JCPP Advances. Guilherme, Guilherme V. Polanczyk reports receiving personal fees from and serving as a speaker and/or consultant for Abbott, Ache, Medice, Novo Nordisk, Takeda and royalties from Editora Manole. Guilherme V. Polanczyk is a Joint Editor for JCPP Advances.